RSS Feeds
Search

Companies

Health Protection Agency

Health Protection Agency
Government Research & Biopharmaceutical Production

The company in detail

Profile

The Health Protection Agency (HPA) was formed on April 1st 2003 by bringing together various sections of the public health system. The Agency was set up to provide an integrated approach to protecting public health and reducing the effects of infections, poisons, chemical and radiation hazards.

Although a public sector body the Agency derrives a significant proportion of its annual turnover from commercial and contract work with UK and foreign governments, industry and academia.

The Agency conducts research into specific hazards to meet current and incipient health problems and to react to national emergencies, and has three national centres as well as a network of laboratories across the country.

The Agency's Centre at Porton Down has licensed GMP manufacturing facilities available for contract manufacture of biologics including recombinant proteins, enzymes and vaccines.

Specialist facilities for the handling of microbial pathogens exist to enable the development of diagnostic,prophylactic and therapeutic products from live agents, with particular reference to the biodefence sector.

Other capabilities include vaccine evaluation services from the development of assays to support for clinical trials, the supply of cell cultures and a wide range of diagnostic services.

Partnering strategy/interests

The Agency has recently formed a technology cluster with three other public sector establishments (Central Science laboratory, Defence Science & Technology Laboratory and Veterinary Laboratories Agency) to facilitate licensing and joint venturing of complementary IP across a range of technology areas.

Services

R&D

To view this information, you must subscribe to Pharmalicensing Intelligence.

Partnerships

To view this information, you must subscribe to Pharmalicensing Intelligence.

Deals

To view this information, you must subscribe to Pharmalicensing Intelligence.

Press Releases

(18th Nov 2011) Salisbury, UK – 18th November 2011 – the Health Protection Agency (HPA) today welcomed the news that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for ERWINAZE™. The application was made by the HPA’s dev More
(15th Sep 2008) Funding to enable the design phase phase has been approved and made available by the UK government More
(17th Jul 2008) Public Sector Research Exploitation Fund: 4th Round. More
(17th Jul 2008) Facility to safely handle and protect samples More
(22nd Jan 2007) The Health Protection Agency (UK) and the Serum Institute of India Ltd have announced that they have signed a royalty-bearing licence to develop a pentavalent vaccine for India and developing countries to combat all the principal forms of meningitis More
(22nd Nov 2005) A life-saving drug which offers potential benefit to children with leukaemia who have become allergic to front line therapies is to be produced by the Health Protection Agency in partnership with OPi Pharmaceuticals. More
(15th Nov 2005) The Health Protection Agency has set up a new company, Syntaxin Ltd, to further realise the health benefits and commercial potential of part of its technology programme, it was announced today. More
(5th Aug 2005) A capability to fill biologicals for clinical trials and niche market products. More
(14th Apr 2005) Potential application to surgical instruments More
(14th Jan 2005) BOTULINUM VACCINE COLLABORATION More
More press releases

Board of directors

To view this information, you must subscribe to Pharmalicensing Intelligence.

Contact details

Dr Philip Luton
Business Development Officer
Commercial

Contact directly

Head office

Health Protection Agency
Porton Down
Salisbury
Wiltshire
SP4 0JG
United Kingdom

Company figures

Formed: 1979
Annual Turnover: 203 M (2005)
Number of employees: 3000

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2012 Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us